BHVN Biohaven Ltd.
Pharmaceutical Preparations · NYSE · SEC CIK 1935979 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY30.4%
TTM EPS YoY49.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-161.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets137.3%
Debt / equity—
Current ratio3.05x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-20.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $101.85M | $100.81M | $103.83M | $121.94M | $141.17M | $184.37M | $187.58M | $167.47M |
| SG&A expense | $24.57M | $24.09M | $26.60M | $20.79M | $28.21M | $27.33M | $33.98M | $22.46M |
| Operating income | -$126.42M | -$124.90M | -$130.43M | -$142.73M | -$169.38M | -$211.70M | -$221.56M | -$189.93M |
| Pretax income | -$129.34M | -$136.92M | -$130.26M | -$145.20M | -$173.22M | -$197.89M | -$221.07M | -$186.79M |
| Income tax | -$64,000 | $391,000 | $272,000 | $351,000 | $221,000 | $261,000 | $609,000 | $48,000 |
| Net income | -$129.28M | -$137.31M | -$130.53M | -$145.56M | -$173.44M | -$198.15M | -$221.68M | -$186.84M |
| EBITDA | -$125.85M | -$124.28M | -$128.06M | -$140.16M | -$168.28M | -$210.64M | -$219.31M | -$187.47M |
| EPS (basic) | -0.86 | -0.91 | -0.88 | — | -1.64 | -1.94 | -2.17 | — |
| EPS (diluted) | -0.86 | -0.91 | -0.88 | — | -1.64 | -1.94 | -2.17 | — |
| Weighted avg. shares (diluted) | 151.04M | 150.64M | 147.62M | — | 105.82M | 102.37M | 101.94M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $95.75M | $238.03M | $273.07M | $229.96M | $184.85M | $165.80M | $98.42M | $102.54M |
| Short-term investments | $65.37M | $29.83M | $74.74M | $89.18M | $75.37M | $239.18M | $224.33M | $386.86M |
| Current assets | $191.51M | $296.56M | $385.65M | $368.33M | $323.62M | $474.83M | $382.76M | $538.47M |
| PP&E, net | $14.70M | $15.09M | $15.26M | $15.96M | $17.52M | $18.59M | $17.79M | $17.32M |
| Goodwill | $1.39M | $1.39M | $1.39M | $1.39M | $1.39M | $1.39M | $1.39M | $1.39M |
| Intangibles | $18.40M | $18.40M | $18.40M | $18.40M | $18.40M | $18.40M | $18.40M | $18.40M |
| Total assets | $263.68M | $370.74M | $466.41M | $451.45M | $409.12M | $550.41M | $458.95M | $615.11M |
| Current liabilities | $62.77M | $62.66M | $52.08M | $115.93M | $113.02M | $124.32M | $164.03M | $154.23M |
| Total liabilities | $361.92M | $358.52M | $336.91M | $399.38M | $426.28M | $415.83M | $199.45M | $191.67M |
| Shareholders' equity | -$98.25M | $12.22M | $129.50M | $52.07M | -$17.16M | $134.59M | $259.50M | $423.44M |
| Shares outstanding | 151.06M | 151.02M | 150.51M | 132.78M | 105.80M | 105.78M | 102.10M | 101.22M |
| Cash flow statement | ||||||||
| Operating cash flow | -$106.85M | -$85.10M | -$149.92M | -$130.66M | -$145.72M | -$167.94M | -$165.12M | -$170.74M |
| Capital expenditure | $180,000 | $454,000 | $0 | $8,000 | $13,000 | $233,000 | $461,000 | $49,000 |
| Free cash flow | -$107.03M | -$85.55M | -$149.92M | -$130.67M | -$145.73M | -$168.17M | -$165.59M | -$170.79M |
| Investing cash flow | -$35.33M | $44.82M | $15.21M | -$13.74M | $164.97M | -$15.55M | $164.88M | -$87.68M |
| Financing cash flow | $211,000 | $3.80M | $179.02M | $188.80M | $122,000 | $249.83M | $369,000 | $272.85M |
| Depreciation & amortization | $569,000 | $621,000 | $2.37M | $2.57M | $1.10M | $1.06M | $2.25M | $2.46M |
| Stock-based compensation | $18.62M | $19.16M | $28.29M | $16.95M | $21.54M | $20.81M | $53.06M | $12.69M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.